Kennedy Capital Management LLC Sells 41,495 Shares of Accuray Incorporated (NASDAQ:ARAY)

Kennedy Capital Management LLC cut its stake in Accuray Incorporated (NASDAQ:ARAY) by 5.4% during the fourth quarter, HoldingsChannel reports. The fund owned 723,438 shares of the medical equipment provider’s stock after selling 41,495 shares during the quarter. Kennedy Capital Management LLC’s holdings in Accuray were worth $1,432,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Prudential Financial Inc. bought a new stake in Accuray during the fourth quarter valued at about $43,000. SG Americas Securities LLC boosted its holdings in shares of Accuray by 37.4% in the 4th quarter. SG Americas Securities LLC now owns 45,079 shares of the medical equipment provider’s stock valued at $89,000 after buying an additional 12,259 shares in the last quarter. Intech Investment Management LLC grew its position in shares of Accuray by 104.1% in the 4th quarter. Intech Investment Management LLC now owns 46,680 shares of the medical equipment provider’s stock worth $92,000 after buying an additional 23,808 shares during the last quarter. Perkins Capital Management Inc. raised its stake in shares of Accuray by 18.3% during the 4th quarter. Perkins Capital Management Inc. now owns 68,000 shares of the medical equipment provider’s stock worth $135,000 after acquiring an additional 10,500 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Accuray during the third quarter valued at approximately $244,000. 64.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Accuray from a “hold” rating to a “buy” rating in a research report on Friday.

Accuray Trading Up 3.4 %

Shares of NASDAQ:ARAY opened at $1.51 on Tuesday. The company has a debt-to-equity ratio of 3.51, a current ratio of 1.62 and a quick ratio of 0.88. The firm has a market capitalization of $155.27 million, a P/E ratio of -30.20 and a beta of 1.30. The business’s 50-day moving average is $1.91 and its 200 day moving average is $1.96. Accuray Incorporated has a 1 year low of $1.40 and a 1 year high of $2.95.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. On average, research analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.